iNtRON Biotechnology, Inc. (KOSDAQ:048530)
South Korea
· Delayed Price · Currency is KRW 3,560.00
+210.00 (6.27%)
Apr 1, 2025, 3:30 PM KST
iNtRON Biotechnology Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 6,418 | 9,585 | 14,007 | 29,308 | 45,433 | Upgrade
|
| Other Revenue | - | -0 | -0 | - | - | Upgrade
|
| Revenue | 6,418 | 9,585 | 14,007 | 29,308 | 45,433 | Upgrade
|
| Revenue Growth (YoY) | -33.05% | -31.57% | -52.21% | -35.49% | 444.28% | Upgrade
|
| Cost of Revenue | 2,738 | 3,802 | 4,412 | 7,614 | 18,982 | Upgrade
|
| Gross Profit | 3,679 | 5,783 | 9,595 | 21,694 | 26,451 | Upgrade
|
| Selling, General & Admin | 4,562 | 6,041 | 5,763 | 6,521 | 6,119 | Upgrade
|
| Research & Development | 3,478 | 3,174 | 3,312 | 3,553 | 3,489 | Upgrade
|
| Other Operating Expenses | 199.93 | 212.56 | 270.75 | 317.09 | 280.48 | Upgrade
|
| Operating Expenses | 8,917 | 9,068 | 11,075 | 11,617 | 10,715 | Upgrade
|
| Operating Income | -5,238 | -3,285 | -1,479 | 10,077 | 15,736 | Upgrade
|
| Interest Expense | -23.41 | -2,919 | -3,506 | -1,636 | -1,184 | Upgrade
|
| Interest & Investment Income | 1,575 | 2,874 | 1,714 | 507.13 | 748.95 | Upgrade
|
| Earnings From Equity Investments | -186.27 | 228.32 | 172.72 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 252.37 | 328.59 | 1,259 | 1,268 | -801.14 | Upgrade
|
| Other Non Operating Income (Expenses) | 77.51 | -328.16 | 11,371 | -39.13 | 1,228 | Upgrade
|
| EBT Excluding Unusual Items | -3,543 | -3,101 | 9,531 | 10,178 | 15,728 | Upgrade
|
| Gain (Loss) on Sale of Investments | -96.64 | -1,986 | -1,142 | 443.93 | 1,087 | Upgrade
|
| Gain (Loss) on Sale of Assets | 633.68 | 6.08 | -70.58 | -46.75 | 63.53 | Upgrade
|
| Other Unusual Items | - | -5,756 | - | - | 172.27 | Upgrade
|
| Pretax Income | -3,006 | -10,837 | 8,319 | 10,575 | 17,051 | Upgrade
|
| Income Tax Expense | -414.72 | -1,141 | 2,607 | 846.81 | 2,103 | Upgrade
|
| Earnings From Continuing Operations | -2,591 | -9,695 | 5,712 | 9,728 | 14,948 | Upgrade
|
| Net Income | -2,591 | -9,695 | 5,712 | 9,728 | 14,948 | Upgrade
|
| Net Income to Common | -2,591 | -9,695 | 5,712 | 9,728 | 14,948 | Upgrade
|
| Net Income Growth | - | - | -41.28% | -34.92% | - | Upgrade
|
| Shares Outstanding (Basic) | 33 | 33 | 34 | 34 | 33 | Upgrade
|
| Shares Outstanding (Diluted) | 33 | 33 | 34 | 34 | 35 | Upgrade
|
| Shares Change (YoY) | -0.87% | -2.16% | 0.58% | -4.41% | 6.08% | Upgrade
|
| EPS (Basic) | -78.75 | -292.11 | 168.38 | 288.42 | 454.94 | Upgrade
|
| EPS (Diluted) | -78.75 | -292.11 | -0.34 | 288.00 | 389.09 | Upgrade
|
| EPS Growth | - | - | - | -25.98% | - | Upgrade
|
| Free Cash Flow | -1,260 | -4,673 | 3,748 | 13,427 | 2,279 | Upgrade
|
| Free Cash Flow Per Share | -38.30 | -140.80 | 110.49 | 398.07 | 64.59 | Upgrade
|
| Dividend Per Share | 100.000 | - | - | - | - | Upgrade
|
| Gross Margin | 57.33% | 60.33% | 68.51% | 74.02% | 58.22% | Upgrade
|
| Operating Margin | -81.61% | -34.27% | -10.56% | 34.38% | 34.64% | Upgrade
|
| Profit Margin | -40.37% | -101.15% | 40.78% | 33.19% | 32.90% | Upgrade
|
| Free Cash Flow Margin | -19.64% | -48.75% | 26.76% | 45.81% | 5.02% | Upgrade
|
| EBITDA | -3,212 | -1,373 | 87.7 | 11,614 | 17,305 | Upgrade
|
| EBITDA Margin | -50.05% | -14.33% | 0.63% | 39.63% | 38.09% | Upgrade
|
| D&A For EBITDA | 2,026 | 1,912 | 1,567 | 1,536 | 1,569 | Upgrade
|
| EBIT | -5,238 | -3,285 | -1,479 | 10,077 | 15,736 | Upgrade
|
| EBIT Margin | -81.61% | -34.27% | -10.56% | 34.38% | 34.64% | Upgrade
|
| Effective Tax Rate | - | - | 31.34% | 8.01% | 12.33% | Upgrade
|
| Advertising Expenses | 41.67 | 70.63 | 29.69 | 34.6 | 25.46 | Upgrade
|
Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.